Steven Cohen's CRNX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2.34 M shares of Crinetics Pharmaceuticals, Inc. (CRNX) worth $108.79 M, representing 0.12% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CRNX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 4.23 M shares. Largest reduction occurred in Q2 2024, reducing 2.17 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Crinetics Pharmaceuticals (CRNX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Crinetics Pharmaceuticals (CRNX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +333,701 | Add 16.66% | 2.34 M | $46.55 |
| Q3 2025 | +5,172 | Add 0.26% | 2 M | $41.65 |
| Q2 2025 | +1.22 M | Add 156.70% | 2 M | $28.76 |
| Q1 2025 | -2.01 M | Reduce 72.09% | 778,398 | $33.54 |
| Q4 2024 | +488,296 | Add 21.22% | 2.79 M | $51.13 |
| Q3 2024 | -480,213 | Reduce 17.27% | 2.3 M | $51.10 |
| Q2 2024 | -2.17 M | Reduce 43.82% | 2.78 M | $44.79 |
| Q1 2024 | +1.53 M | Add 44.85% | 4.95 M | $46.81 |
| Q4 2023 | -808,400 | Reduce 19.13% | 3.42 M | $35.58 |
| Q3 2023 | +4.23 M | New Buy | 4.23 M | $29.74 |
| Q2 2023 | -226,400 | Sold Out | 0 | $0.00 |
| Q1 2023 | -1.13 M | Reduce 83.37% | 226,400 | $16.06 |
| Q4 2022 | +50,800 | Add 3.88% | 1.36 M | $18.30 |
| Q3 2022 | -22,600 | Reduce 1.70% | 1.31 M | $19.64 |
| Q2 2022 | +126,462 | Add 10.48% | 1.33 M | $18.65 |
| Q1 2022 | +101,862 | Add 9.22% | 1.21 M | $21.95 |
| Q4 2021 | +654,676 | Add 145.55% | 1.1 M | $28.41 |
| Q3 2021 | -258,333 | Reduce 36.48% | 449,800 | $21.05 |
| Q2 2021 | -566,867 | Reduce 44.46% | 708,133 | $18.85 |
| Q1 2021 | +49,997 | Add 4.08% | 1.28 M | $15.28 |
| Q4 2020 | +713,015 | Add 139.26% | 1.23 M | $14.11 |
| Q3 2020 | +117,156 | Add 29.67% | 511,988 | $15.67 |
| Q2 2020 | +394,832 | New Buy | 394,832 | $17.52 |
| Q1 2020 | -33,865 | Sold Out | 0 | $0.00 |
| Q4 2019 | -98,135 | Reduce 74.34% | 33,865 | $25.10 |
| Q3 2019 | +132,000 | New Buy | 132,000 | $15.04 |
Steven Cohen's Crinetics Pharmaceuticals Investment FAQs
Steven Cohen first purchased Crinetics Pharmaceuticals, Inc. (CRNX) in Q3 2019, acquiring 132,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Crinetics Pharmaceuticals, Inc. (CRNX) for 26 quarters since Q3 2019.
Steven Cohen's largest addition to Crinetics Pharmaceuticals, Inc. (CRNX) was in Q3 2023, adding 4,225,300 shares worth $125.66 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,337,034 shares of Crinetics Pharmaceuticals, Inc. (CRNX), valued at approximately $108.79 M.
As of the Q4 2025 filing, Crinetics Pharmaceuticals, Inc. (CRNX) represents approximately 0.12% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Crinetics Pharmaceuticals, Inc. (CRNX) was 4,949,486 shares, as reported at the end of Q1 2024.